Drug Discovery Targeting Drug-Resistant Bacteria

Dr. Prashant Kesharwani is an assistant professor of pharmaceutics at School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 300 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community. Dr. Sidharth Chopra is a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~35 international publications in well reputed journals. One of his article is published in Bioresource technology 77 (3), 215-227 with 999 citations and he has extensively worked on discovery and development of NCE against ESKAPE, mycobacterial infections as well as biothreat pathogens. Dr. Arunava Dasgupta a Senior Scientist, at Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, India. He has ~20 international publications in well reputed journals. He has extensively worked on discovery and development of NCE against mycobacterial infections as well as understanding hostpathogen interaction.

1. What are drugs and why are they required?2. Drugs against gram-negative bacteria3. Drugs targeting gram-positive bacteria4. Drug repurposing against bacteria5. Drugs against M. tuberculosis6. Drugs against TB and Bioweapons7. New approaches to drug discovery: Peptides/quorum sensing/virulence8. New strategies and targets for antibacterial discovery9. Targeting efflux pumps for AMR10. Discovering antibiotics from Phages11. Drugs against non-tuberculous mycobacteria